Anrotinib is an antitumor-targeted drug with the most serious side effects such as severe bleeding and ventricular tachyarrhythmia, and should be used strictly under medical supervision.
Anrotinib is an anti-tumor targeted drug. It is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer that has progressed or recurred after systemic chemotherapy, etc.
However, it should not be used in patients with a history of allergy to the components of this drug, patients with central squamous lung cancer or patients at risk of hemoptysis, and it is also contraindicated in patients with severe hepatic or renal insufficiency, and in pregnant and lactating women.
Adverse reactions such as hypertension, sinus tachycardia, abdominal pain, diarrhea, proteinuria, hyperlipidemia, fatigue, and weight loss are common with the use of Anrotinib. The most serious and concerning is the risk of bleeding, including hemoptysis and gastrointestinal bleeding, which may be life-threatening, followed by the possibility of prolongation of the QT interval, increasing the risk of ventricular tachyarrhythmias and even sudden death.
In summary, Anrotinib must be used under the guidance of a doctor in strict compliance with medical advice, and should pay close attention to platelets, coagulation function and other indicators of the examination, to avoid the occurrence of serious adverse reactions, and if there is any discomfort in the use of the process, you should immediately seek medical attention.